RCS - Physiomics PLC - DoseMe Precision Dosing - Modeling & Functionality

PhysiomicsAnnouncement

14/06/2024 08:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240614:nRSN4783Sa&default-theme=true

RNS Number : 4783S  Physiomics PLC  14 June 2024

14 June 2024

 

 

Physiomics plc

("Physiomics" or the "Company")

 

Physiomics Adds Modeling and Data Science Functionality to DoseMe's Precision
Dosing Platform

 

Physiomics plc (AIM: PYC), a leading mathematical modelling and data science
company supporting the development of new therapeutics and personalised
medicine solutions, is pleased to announce that it has re-engaged with DoseMe
(https://doseme-rx.com/) and agreed to implement the Company's personalised
dosing software on the DoseMeRx platform as well as explore research
collaborations.  The Physiomics software will be made available to selected
DoseMe clients, initially on a research basis, but with the objective of
adding paid functionality later, in particular relating to the potential for
the software to be able to provide decision support around the use of
granulocyte colony stimulating factor ("GCSF").

Background

The Company's personalised dosing software has been developed primarily with
grant funding from UK bodies including £68,000 from Innovate UK (March 2018),
£150,000 from the National Institute for Health and Care Research to fund the
PARTNER study (March 2020) and most recently £137,376 from Innovate UK and
The Office for Life Sciences to fund the PREDICT-ONC study (November 2023).

The software was initially focused on cancer chemotherapies (such as
docetaxel) that can cause reduced white cell counts (neutropenia) and
potentially lead to infection and hospitalisation.  Based on a series of
blood tests in the early weeks of a patient's chemotherapy treatment, the
software is calibrated for each individual to provide an estimate of the
extent and timing of neutropenia.  It also allows clinicians to amend the
dose of chemotherapy and see the predicted effect on neutrophil levels.

Collaboration with DoseMe

The Company first entered into a collaboration with DoseMe at the end of 2020
and the two companies worked together during 2021 to implement a demonstration
version of the Physiomics software to facilitate review with US based
pharmacists and clinicians.  Feedback from this exercise suggested that the
need for additional blood tests to calibrate the software could be a
disincentive to its use and that, in addition, some focus on more modern,
costly drugs would be of interest.  During 2022 DoseMe's then parent company
announced its planned divestment and DoseMe was acquired by a private equity
group in early 2023.  During that year, in parallel with applying for and
winning a further Innovate UK grant, the Company re-engaged with DoseMe's new
management, culminating in today's announcement of the plan to launch the
Company's dosing software on the recently upgraded and expanded DoseMeRx
platform and to make it available, initially on a research basis, to selected
US clients.  It is expected that the software will be made available in the
second half of 2024.  The two companies have also agreed to identify one or
more centres in the US, currently served by DoseMe, that have historical
patient data that could be used to further develop Physiomics' dosing software
and specifically to enhance its ability to support decision making around the
use of the expensive biological drug GCSF which is commonly used by clinicians
to counteract the neutropenic tendency of chemotherapeutic agents.

Moving Forwards

The focus of the Company's personalised dosing initiatives going forwards will
be to expand the capability of the software to support dosing decision making
around not only chemotherapeutic agents but GCSF.  Both the ongoing
PREDICT-ONC study and potential secondary research with DoseMe clients in the
US will support this objective.  In parallel, the Company is seeking ways to
make the blood sampling required by its software more convenient for
patients.  This can potentially be achieved by using the software in other
settings where frequent blood sampling already occurs, but also through
exploration of the use of new diagnostic devices that can obtain and analyse
blood samples in community or home settings (such at that being developed by
our partner company Beyond Blood Diagnostics).

As the Company continues to develop its personalised dosing software, it will
actively consider the most appropriate way to ring fence resources for this
part of its business.  Options under consideration include creation of a
dedicated business unit, creation of a wholly owned subsidiary or a joint
venture with a party with complementary technology/ capabilities.  As further
progress is made towards one of these, further updates will be provided
accordingly.

Dr Peter Sargent, CEO, commented: "I'm really pleased that we've able to
progress this initiative and the team are excited to build upon the
partnership with DoseMe to further develop our Personalised Oncology Dosing
Software".

 

Paul Edwards, CEO, DoseMe, commented: "Oncology is one area that will benefit
tremendously from precision dosing. The results from the initial research
point to constructive data output that will enhance dosing decision and
ultimately, make life changing differences for patients."

 

 

Enquiries:

 

Physiomics plc

Dr Peter Sargent, CEO

+44 (0)1235 841575

 

Hybridan LLP (Broker)

Claire Louise Noyce

+44 (0) 203 764 2341

 

Strand Hanson Ltd (NOMAD)

James Dance & James Bellman

+44 (0)20 7409 3494

 

DoseMe

Alison Guzzio

+1 484 459 3243

 

 

 

Notes to Editor

 

About Physiomics

 

Physiomics plc combines cutting edge PKPD and QSP modelling and data science
techniques, along with deep biology expertise, to help biotech and pharma
companies streamline their drug development journeys.

Our approach is to derive insight from all relevant data in order to de-risk
decision making and optimise design research across discovery, pre-clinical
and clinical studies.

Through use of bespoke models and our proprietary Virtual Tumour technology,
the Physiomics team has informed the development of over 100 commercial
projects, over 50 targets and 75 drugs. Clients include Merck KGaA, Astellas,
Bicycle Therapeutics, Numab Therapeutics & CRUK.

 

About DoseMe

DoseMe combines smart technology with science, leveraging clinically-validated
PK/PD models, patient characteristics, drug concentrations, and genotype to
accurately individualize a dose in seconds. The platform is HIPAA, ISO &
FDA compliant and the only Bayesian dosing platform to be HITRUST CSF
certified. For more information on successful applications of its products,
DoseMeRx and DoseMe Analytics, visit https://doseme-rx.com/success-stories
(https://doseme-rx.com/success-stories)

 

 

 

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAFIFSRRSISLIS